Kyle Doherty


Adjuvant nivolumab benefit in urothelial carcinoma sustained with longer follow-up

May 14, 2022

Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.

Dr. Petrylak highlights the latest advances in metastatic urothelial cancer

March 22, 2022

In discussing treatment determinations, Petrylak noted that for patients with low PD-L1 expression had decreased survival benefits compared with patients treated with chemotherapy in the monotherapy arms of the phase 3 KEYNOTE-361 (NCT02853305) and phase 3 IMVIGOR-130 (NCT02807636) trials.